JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on ABSI stock, giving a Buy rating on November 25.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Debanjana Chatterjee’s rating is based on the strategic shift in AbSci’s focus towards ABS-201, which shows promising potential in the androgenetic alopecia (AGA) market. The decision to prioritize ABS-201 over ABS-101 is driven by the potential for higher risk-adjusted returns, as ABS-201 is positioned to capture a significant share of the multi-billion dollar AGA market in the United States. The product’s competitive profile, including its potentially higher efficacy compared to the standard of care and anticipated multi-year durability, supports this strategic focus.
Furthermore, the decision to explore ABS-201 for endometriosis is backed by positive Phase 2 results from a similar treatment, which reduces clinical risk and highlights the opportunity in a market with limited competition. The cost-effectiveness of endometriosis trials compared to full Phase 2 studies for inflammatory bowel disease (IBD) also presents a favorable return on investment. These factors collectively underpin the Buy rating, reflecting confidence in ABS-201’s potential to drive significant future growth for AbSci.